1,178
Views
2
CrossRef citations to date
0
Altmetric
Editorials: Cell Cycle Features

Small molecule induces Wnt asymmetry in cancer

, &
Pages 141-142 | Received 31 Aug 2016, Accepted 08 Sep 2016, Published online: 01 Nov 2016

References

  • Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434:843-50; PMID:15829953; http://dx.doi.org/10.1038/nature03319
  • Bajaj J, Zimdahl B, Reya T. Fearful Symmetry: Subversion of asymmetric division in cancer development and progression. Cancer Res 2015; 75:792-797; PMID:25681272; http://dx.doi.org/10.1158/0008-5472.CAN-14-2750
  • Quyn AJ, Appleton PL, Carey FA, Steele RJC, Barker N, Clevers H, Ridgway RA, Sansom OJ, Näthke IS. Spindle orientation bias in gut epithelial stem cell compartments is lost in precancerous tissue. Cell Stem Cell 2010; 6:175-181; PMID:20144789; http://dx.doi.org/10.1016/j.stem.2009.12.007
  • Qu Y, Gharbi N, Yuan X, Olsen JR, Blicher P, Dalhus B, Brokstad KA, Lin B, Øyan AM, Zhang W, et al. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proc Natl Acad Sci U S A 2016; 113:9339-44; PMID:27482107; http://dx.doi.org/10.1073/pnas.1604520113
  • Conboy MJ, Karasov AO, Rando TA. High incidence of non-random template strand segregation and asymmetric fate determination in dividing stem cells and their progeny. PLoS Biol 2007; 5:e102; PMID:17439301; http://dx.doi.org/10.1371/journal.pbio.0050102
  • Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al. Nonclinical antiangiogenesis and antitumor activities of Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14:7272-7283; PMID:19010843; http://dx.doi.org/10.1158/1078-0432.CCR-08-0652
  • Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4:682-690; PMID:18936753; http://dx.doi.org/10.1038/nchembio.118

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.